TY  - JOUR
AU  - Gisbert, J. P.
AU  - Romano, M.
AU  - Gravina, A. G.
AU  - Solis-Munoz, P.
AU  - Bermejo, F.
AU  - Molina-Infante, J.
AU  - Castro-Fernandez, M.
AU  - Ortuno, J.
AU  - Lucendo, A. J.
AU  - Herranz, M.
AU  - Modolell, I.
AU  - del Castillo, F.
AU  - Gomez, J.
AU  - Barrio, J.
AU  - Velayos, B.
AU  - Gomez, B.
AU  - Dominguez, J. L.
AU  - Miranda, A.
AU  - Martorano, M.
AU  - Algaba, A.
AU  - Pabon-Carrasco, Manuel
AU  - Angueira, T.
AU  - Fernandez-Salazar, L.
AU  - Federico, A.
AU  - Marin, A. C.
AU  - McNicholl, A. G.
PY  - 2015
DO  - 10.1111/apt.13128
SN  - 0269-2813
UR  - https://hdl.handle.net/10668/28461
T2  - Alimentary Pharmacology and Therapeutics
AB  - Background: The most commonly used second-line Helicobacter pylori eradication regimens are bismuth-containing quadruple therapy and levofloxacin-containing triple therapy, both offering suboptimal results. Combining bismuth and levofloxacin may...
LA  - en
PB  - Wiley
KW  - Concomitant therapy
KW  - Sequential therapy
KW  - Eradication
KW  - Infection
KW  - Resistence
KW  - Efficacy
KW  - Helicobacter Infections
KW  - Anti-Bacterial Agents
KW  - Drug Resistance, Bacterial
KW  - Proton Pumps Inhibitors
KW  - Bismuth
TI  - Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments
TY  - research article
VL  - 41
ER  -